title: Further Stimulation of Cellular Immune Responses through Association of HPV-16 E6, E7 and L1 Genes in order to produce more Effective Therapeutic DNA Vaccines in Cervical Cancer Model.
abstract: BACKGROUND
  Cervical cancer has been shown to be highly associated with human papillomavirus (HPV) infection. The viral oncogenes E6 and E7 are constantly expressed by the tumor cells and are therefore potent targets for therapeutic genetic vaccination. In the present study, it was investigated the potential effect of HPV-16 E6, E7 and L1 co-administration to activate specific cytotoxic T lymphocytes in tumor mice models.
  
  
  METHODS
  The HPV-16 E6, E7 and L1 genes from Iranian isolate were separately inserted into the mammalian expression vector, pcDNA3, to construct the DNA vaccine candidates. Tumor-bearing Animals (C57BL/6 mice) were immunized with the vaccine candidate; then, Lymphocyte Proliferation Assay (LPA) and relative tumor volume measurements were carried out in order to examine the immunological effects of the vaccine.
  
  
  RESULTS
  Obtained results showed that co-administration of the HPV-16 E6, E7 and L1 DNA induced HPV-16 specific cellular immune responses and also protected against TC-1-induced tumor in vivo compared with negative controls.
  
  
  CONCLUSIONS
  The results showed that mixed delivery systems might be valuable to improve the magnitude of the induced immune responses and confirmed therapeutic effects of HPV-16 E6, E7 through cytotoxic T lymphocyte induction and illustrate the new promising role for HPV-16 L1 CTL epitopes as a suitable CTL inducer.
authors.affiliation: Dept. of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
authors.forename: Maryam
authors.initials: M
authors.lastname: Fazeli
authors.affiliation: Dept. of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
authors.forename: Hoorieh
authors.initials: H
authors.lastname: Soleimanjahi
authors.affiliation: Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences Tehran, Iran.
authors.forename: Simin
authors.initials: S
authors.lastname: Dadashzadeh
keywords: immunocellular responses; pcDNA3/E6; pcDNA3/E7; pcDNA3/L1
references.citation: Iran J Cancer Prev. 2012 Winter;5(1):16-20
references.pmid: 25780534
references.citation: Nat Rev Immunol. 2009 Aug;9(8):568-80
references.pmid: 19629084
references.citation: Vaccine. 2004 Dec 16;23(5):629-38
references.pmid: 15542183
references.citation: J Virol. 1996 Jul;70(7):4509-16
references.pmid: 8676476
references.citation: Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1800-5
references.pmid: 9465097
references.citation: Annu Rev Immunol. 2000;18:927-74
references.pmid: 10837079
references.citation: Eur Rev Med Pharmacol Sci. 2013 Jan;17(2):228-34
references.pmid: 23377813
references.citation: Int J Cancer. 2001 Apr 15;92 (2):285-93
references.pmid: 11291058
references.citation: Med Microbiol Immunol. 2015 Apr;204(2):205-13
references.pmid: 25187406
references.citation: Expert Rev Anticancer Ther. 2007 Oct;7(10):1473-86
references.pmid: 17944571
references.citation: J Virol. 2009 Jul;83(13):6779-89
references.pmid: 19386711
references.citation: Saudi Med J. 2008 Aug;29(8):1105-8
references.pmid: 18690300
references.citation: Med Microbiol Immunol. 1992;180(6):321-6
references.pmid: 1312661
references.citation: Gynecol Oncol. 2009 Dec;115(3 Suppl):S15-23
references.pmid: 19819540
references.citation: Cancer Res. 1996 Jan 1;56(1):21-6
references.pmid: 8548765
references.citation: J Natl Cancer Inst. 2001 Dec 19;93(24):1843-51
references.pmid: 11752008
references.citation: J Natl Cancer Inst. 1995 Jun 7;87(11):796-802
references.pmid: 7791229
references.citation: Cancer Res. 1997 Jul 15;57(14):2943-50
references.pmid: 9230206
references.citation: Virology. 2010 Jan 5;396(1):118-24
references.pmid: 19906396
references.citation: Nihon Rinsho. 2009 Jan;67(1):62-8
references.pmid: 19177753
references.citation: J Virol. 1999 Nov;73(11):9063-71
references.pmid: 10516012
references.citation: J Cancer Res Clin Oncol. 1983;105(1):20-3
references.pmid: 6833336
references.citation: J Infect Dis. 2003 Jul 15;188(2):327-38
references.pmid: 12854090
references.citation: Vaccine. 2009 Jan 14;27(3):431-40
references.pmid: 19022315
references.citation: Lancet Oncol. 2001 Sep;2(9):533-43
references.pmid: 11905707
references.citation: Iran J Immunol. 2008 Jun;5(2):82-91
references.pmid: 18523353
references.citation: J Virol. 2003 Jan;77(2):1551-63
references.pmid: 12502868
references.citation: J Clin Pathol. 2002 Apr;55(4):244-65
references.pmid: 11919208
references.citation: Scand J Immunol. 2009 Oct;70(4):326-36
references.pmid: 19751267